Keros Therapeutics

KROS

Market cap $636M

Overview Fund Activity

15.66 USD

-0.10

0.63%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

15.66

0.00

0%

1 day

-0.63%

5 days

0.45%

1 month

14.22%

3 months

14.81%

6 months

33.16%

Year to date

-1.63%

1 year

-72.23%

5 years

-65.26%

10 years

-22.01%

About: Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Employees: 148

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

74% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 34

33% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 4 (+1) [Q2]

12% more capital invested

Capital invested by funds: $429M [Q1] → $480M (+$51M) [Q2]

2.12% less ownership

Funds ownership: 90.59% [Q1] → 88.46% (-2.12%) [Q2]

12% less funds holding

Funds holding: 156 [Q1] → 138 (-18) [Q2]

19% less call options, than puts

Call options by funds: $13.3M | Put options by funds: $16.4M

40% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 43

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$20

28% upside

Avg. target

$20

28% upside

High target

$20

28% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co.

Andres Y. Maldonado

$20

Buy

Maintained

8 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about KROS published over the past 30 days

Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting

LEXINGTON, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it presented additional clinical data from its Phase 1 clinical trial of KER-065 in healthy male volunteers at the American Society of Bone and Mineral Research 2025 Annual Meeting on Saturday, September 6, 2025.

Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

LEXINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare conferences:

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment

AUSTIN, Texas , Aug. 21, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "we"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today released an open letter to Keros' Board of Directors (the "Board") expressing its disappointment with the Board's refusal to engage with ADAR1 on the Company's strategy, capital allocation priorities and Board refreshment. The full text of the letter is below.

ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment

Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced the U.S. Food and Drug Administration (“FDA”) granted Orphan Drug designation for KER-065 for the treatment of Duchenne muscular dystrophy (“DMD”).

Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

Zacks Investment Research

Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates

Keros Therapeutics, Inc. (KROS) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $1.25 per share a year ago.

Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced a strategic realignment designed to reallocate resources towards the development of its key clinical program, KER-065.

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

Keros Therapeutics Reports Second Quarter 2025 Financial Results

LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today reported financial results for the quarter ended June 30, 2025.

Keros Therapeutics Reports Second Quarter 2025 Financial Results

Zacks Investment Research

KROS vs. EXAS: Which Stock Should Value Investors Buy Now?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Keros Therapeutics, Inc. (KROS) and Exact Sciences (EXAS). But which of these two stocks is more attractive to value investors?

KROS vs. EXAS: Which Stock Should Value Investors Buy Now?

Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept

LEXINGTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that the first patient was dosed in the Phase 3 RENEW clinical trial of elritercept in adults with transfusion-dependent anemia with very low, low, or intermediate risk myelodysplastic syndromes (“MDS”).

Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept

ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal

Significant Withhold Votes from Directors Mary Ann Gray and Alpna Seth Underscores Need for Change and a More Disciplined Capital Allocation Strategy AUSTIN, Texas , June 9, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "We"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Company"), today issued the following statement regarding the results of the Company's 2025 Annual Meeting of Stockholders (the "Annual Meeting"): "We believe the outcome of the Annual Meeting underscores what we have consistently conveyed to Keros' Board of Directors: there is broad and growing concern among stockholders regarding the Board's capital allocation decisions and fidelity to stockholder interests. ADAR1 previously disclosed its intention to withhold votes from Dr. Mary Ann Gray and Dr. Alpna Seth at the Annual Meeting.

ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal

See News Rankings

Charts implemented using Lightweight Charts™